Migraine drug delay would compound Teva's troubles

TEL AVIV (Reuters) - Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.